Cardiff Oncology, Inc. (CRDF) vs ImmuCell Corporation (ICCC)
A side-by-side comparison of Cardiff Oncology, Inc. and ImmuCell Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRDF
Cardiff Oncology, Inc.
$1.09HealthcareDelayed quote: Oct 6, 2026, 2:56 PM EDT
ICCC
ImmuCell Corporation
$9.90HealthcareDelayed quote: Oct 6, 2026, 2:57 PM EDT
Total return — CRDF vs ICCC
growth of $100 · dividends reinvested · last 10yCRDF -99.6% (-43.1%/yr)ICCC +26.0% (+2.3%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
CRDF ICCC
CRDF vs ICCC: by the numbers
- •ICCC is the larger company ($90M vs $84M market cap).
- •ICCC is profitable (2.57% net margin) while CRDF runs a net loss (-7884.06%).
- •ICCC grew revenue faster over the past five years (13.74% vs 5.15% CAGR).
Metrics side by side
Valuation
| Metric | CRDF | ICCC |
|---|---|---|
| P/E ratio | N/A | 117.02 |
| P/S ratio | 164.62 | 2.92 |
| P/B ratio | 3.15 | 2.85 |
| EV / EBITDA | N/A | 14.90 |
| FCF yield | N/A | 4.71% |
Profitability
| Metric | CRDF | ICCC |
|---|---|---|
| Gross margin | 100.00% | 40.32% |
| Operating margin | -8256.32% | 12.60% |
| Net margin | -7884.06% | 2.57% |
| ROE | -150.95% | 2.51% |
| ROIC | -159.30% | 8.16% |
Growth (annualized)
| Metric | CRDF | ICCC |
|---|---|---|
| Revenue CAGR (5Y) | 5.15% | 13.74% |
| Total return CAGR (5Y) | -30.36% | 0.65% |
Frequently asked
- Which has grown faster, CRDF or ICCC?
- Over the past five years, ICCC grew revenue faster — CRDF at a 5.15% CAGR versus ICCC at 13.74%.
- Is CRDF or ICCC more profitable?
- ICCC runs the higher net margin — CRDF at -7884.06% versus ICCC at 2.57%.
- How have CRDF and ICCC total returns compared?
- Over the past 10 years, CRDF delivered -43.20% and ICCC delivered 2.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmuCell P/E ratioCardiff Oncology ROEImmuCell ROECardiff Oncology operating marginImmuCell operating marginCardiff Oncology revenue growthImmuCell revenue growthCardiff Oncology free cash flowImmuCell free cash flow
Cardiff Oncology & ImmuCell appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.